Immuneering (IMRX) Profit After Tax (2020 - 2026)

Immuneering's Profit After Tax history runs 7 years deep, the most recent figure standing at -$13.8 million for Q1 2026.

• On a quarterly basis, Profit After Tax rose 8.39% year-over-year to -$13.8 million in Q1 2026; TTM through Mar 2026 was -$54.7 million, a 11.48% increase from a year earlier, with the FY2025 full-year figure at -$55.9 million, up 8.34% from the prior year.
• Profit After Tax eased to -$13.8 million in Q1 2026 per IMRX's latest filing, from -$11.5 million in the prior quarter.
• Across five years, Profit After Tax topped out at $38.4 million in Q4 2023 and bottomed at -$18.1 million in Q4 2024.
• The 5-year median for Profit After Tax is -$12.9 million (2022), against an average of -$6.2 million.
• Across the five-year window, Profit After Tax surged 445.9% in 2022 and tumbled 85942.27% in 2023, its largest moves.
• Year by year, Profit After Tax stood at $37.3 million in 2022, then grew by 2.94% to $38.4 million in 2023, then tumbled by 147.03% to -$18.1 million in 2024, then surged by 36.3% to -$11.5 million in 2025, then declined by 19.87% to -$13.8 million in 2026.
• Per Business Quant, the three latest IMRX Profit After Tax figures stand at -$13.8 million (Q1 2026), -$11.5 million (Q4 2025), and -$15.0 million (Q3 2025).